{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"8.03","value":"6.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"description":"Pre-dose concentrations were applied as 24-hour concentrations in order to calculate steady-state PK parameters.","dispersionType":"Full Range","groups":[{"description":"Participants were randomized to ibrutinib 560 mg and venetoclax (starting at 20 mg, and gradually ramped up to a target dose of 400 mg) for approximately 104 weeks, followed by ibrutinib monotherapy until disease progression (PD), unacceptable toxicity or withdrawal of consent. Venetoclax was discontinued after 104 weeks of treatment, regardless of response assessment.","id":"OG000","title":"Randomization Phase: Ibrutinb + Venetoclax"}],"paramType":"MEDIAN","populationDescription":"Participants receiving venetoclax with an evaluable PK assessment at given time point.","reportingStatus":"POSTED","timeFrame":"Week 6, Day 1: Predose, at Dose, 1 hour (± 15 minutes [min]), 2 hours (± 15 min), 4 hours (± 30 min), 6 hours (± 30 min), 8 hours (± 1 hour), 24 hours post-dose","title":"Steady-State PK of Venetoclax: Time to Cmax (Tmax) (Randomization Phase)","type":"SECONDARY","unitOfMeasure":"hours"}